Maintenance of Remission in Ulcerative Colitis |
| |
| Authors: | P.S. DAVIES,M B.,B.S.,M R.C.P., J. RHODESM.B.,Ch.B.,M.D.,F.R.C.P.,&dagger BARBARA COUNSELL,MB.,B.Ch.,&Dagger B. K. EVANS,B Pharm.,M.P.S. |
| |
| Affiliation: | Glamorgan, U. K.;Cardiff, U. K. |
| |
| Abstract: | PRD-y2 a well-absorbed mast cell stabilizer was examined in patients with ulcerative colitis by a double-blind controlled trial. Forty-three patients who were in clinical remission and taking sulfasalazine were randomly allocated to treatment with sulfasalazine or PRD-92 for six months. Relapses occurred in 42% of patients on PRD-92 and 24% on sulfasalazine. PRD-92 has a less prophylactic effect than sulfasalazine in ulcerative colitis. |
| |
| Keywords: | |
|
|
